Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 11:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 329 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo or sugar pill Clear all
Terminated Phase 4 Interventional Results available

Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects

NCT01349114
View directory record Official record
Conditions
Diabetes, Pre-hypertension, Hypertension
Interventions
aliskiren 300 mg once daily, Placebo/sugar pill
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 12, 2026, 11:55 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet

NCT01072669
View directory record Official record
Conditions
Ischemia
Interventions
ambrisentan
Drug
Lead sponsor
Soumya Chatterjee
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 12, 2026, 11:55 PM EDT
Terminated Phase 4 Interventional Results available

Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance

NCT01681264
View directory record Official record
Conditions
Chronic Pain
Interventions
Morphine, Guanfacine 1mg, Guanfacine 2mg, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 12, 2026, 11:55 PM EDT
Completed Phase 4 Interventional Results available

DECIFER: Depression and Citalopram In First Episode Recovery

NCT01041274
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorder
Interventions
Citalopram, Placebo, Psychoeducation, Cognitive Behavioral Therapy (CBT), Functional Magnetic Resonance Imaging (fMRI)
Drug · Behavioral · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years to 40 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 12, 2026, 11:55 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy

NCT01694966
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Methylene Blue MMX®, Placebo
Drug
Lead sponsor
Cosmo Technologies Ltd
Industry
Eligibility
50 Years to 75 Years
Enrollment
1,249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
7
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Lafayette, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 12, 2026, 11:55 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy

NCT06065670
View directory record Official record
Conditions
Demyelinating Diseases, Demyelination; Corpus Callosum, Multiple Sclerosis Brain Lesion, Multiple Sclerosis Acute and Progressive, Clinically Isolated Syndrome, CNS Demyelinating
Interventions
Clemastine Fumarate, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 12, 2026, 11:55 PM EDT
Terminated Phase 3 Interventional Results available

52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT02120027
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Ibodutant 10 mg, Placebo
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
18 Years and older · Female only
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
73
States / cities
Chandler, Arizona • Glendale, Arizona • Mesa, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 12, 2026, 11:55 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease

NCT00838396
View directory record Official record
Conditions
GERD
Interventions
XP19986 CR, Placebo for XP19986 CR
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
Stanford, California • Charleston, South Carolina • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Oct 12, 2026, 11:55 PM EDT
Completed Phase 2 Interventional

Comparison of MMFS Dosages in Older Adults

NCT03601169
View directory record Official record
Conditions
Anxiety, Depression, Sleep Quality, Cognitive Impairment
Interventions
Low Dose MMFS-205-SR, High Dose MMFS-205-SR, Placebo
Dietary Supplement
Lead sponsor
Neurocentria, Inc.
Industry
Eligibility
60 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 12, 2026, 11:55 PM EDT
Completed Phase 4 Interventional Results available

Memantine and Cognitive Dysfunction in Bipolar Disorder

NCT00586066
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Memantine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 12, 2026, 11:55 PM EDT
Completed Phase 2 Interventional

A Study of Cabergoline for the Treatment of Cocaine Dependence - 1

NCT00033111
View directory record Official record
Conditions
Cocaine-Related Disorders, Substance-Related Disorders
Interventions
Cabergoline, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 99 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
2
States / cities
Torrance, California • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 12, 2026, 11:55 PM EDT
Completed Phase 4 Interventional Results available

Validation of Dyskinesia Rating Scales

NCT01071395
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Amantadine, Placebo
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
30 Years to 90 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Birmingham, Alabama • Tampa, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Oct 12, 2026, 11:55 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children

NCT00468130
View directory record Official record
Conditions
Autism
Interventions
Aripiprazole, Placebos
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
5 Years to 17 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 12, 2026, 11:55 PM EDT
Suspended Phase 3 Interventional Accepts healthy volunteers

The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents

NCT05289557
View directory record Official record
Conditions
Morning Sickness
Interventions
Bonjesta, Placebo
Drug
Lead sponsor
Duchesnay Inc.
Industry
Eligibility
12 Years to 17 Years · Female only
Enrollment
274 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
10
States / cities
Burbank, California • Hialeah, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 12, 2026, 11:55 PM EDT
Completed Phase 2 Interventional

Gabapentin and Tizanidine for Insomnia in Chronic Pain

NCT04429347
View directory record Official record
Conditions
Insomnia Due to Medical Condition, Chronic Pain
Interventions
Gabapentin, Placebo, Tizanidine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 3, 2025 · Synced Oct 12, 2026, 11:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents With Anxiety

NCT02818751
View directory record Official record
Conditions
Anxiety
Interventions
Escitalopram, Placebo
Drug · Other
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 12, 2026, 11:55 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

NCT02319837
View directory record Official record
Conditions
Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Interventions
Enzalutamide, Placebo (No longer applicable in Open Label study period), Leuprolide Open Label
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,068 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
77
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 12, 2026, 11:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Multimodal Neuroimaging of Treatment Effects in Adolescent Mania

NCT00893581
View directory record Official record
Conditions
Mania, Bipolar Disorder
Interventions
Quetiapine & Placebo, Lithium and Placebo, Healthy Controls
Drug · Other
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 17 Years
Enrollment
169 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 12, 2026, 11:55 PM EDT
Completed Not applicable Interventional Results available

Eplerenone for the Treatment of Central Serous Chorioretinopathy

NCT01990677
View directory record Official record
Conditions
Central Serous Chorioretinopathy
Interventions
25mg Eplerenone, Placebo
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
10
States / cities
Cherry Hill, New Jersey • Marlton, New Jersey • Mays Landing, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 12, 2026, 11:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Varenicline and Nicotine Interactions in Humans (VA)

NCT00606892
View directory record Official record
Conditions
Smoking Cessation
Interventions
Varenicline, Placebo, IV Nic
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 12, 2026, 11:55 PM EDT
Withdrawn Phase 2 Interventional

Rifaximin Treatment of Papulopustular Rosacea

NCT01359228
View directory record Official record
Conditions
Rosacea
Interventions
Rifaximin (XIFAXAN), Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Oct 12, 2026, 11:55 PM EDT
Completed Phase 1 Interventional

Main Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients

NCT01650649
View directory record Official record
Conditions
Opioid Dependence, Methadone Withdrawal Syndrome
Interventions
Lofexidine HCl, Lofexidine-matching sugar pill
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years to 60 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 12, 2026, 11:55 PM EDT
Completed Phase 4 Interventional Results available

Pharmacogenetic Response to Naltrexone For Alcohol Dependence

NCT00831272
View directory record Official record
Conditions
Alcohol Dependence
Interventions
naltrexone, Placebo
Drug
Lead sponsor
David Oslin
Other
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
4
States / cities
Danville, Pennsylvania • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 12, 2026, 11:55 PM EDT
Completed Phase 1 Interventional

Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer

NCT00976131
View directory record Official record
Conditions
Breast Cancer
Interventions
CoQ10, CoQ10 Placebo, Doxorubicin, Cyclophosphamide
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
21 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Oct 12, 2026, 11:55 PM EDT